Feline Sporotrichosis

Feline sporotrichosis is a subcutaneous mycotic infection caused by thermodimorphic fungi belonging to the Sporothrix schenckii species complex, most notably Sporothrix brasiliensis [1]. It is considered the most clinically significant and epidemiologically important fungal zoonosis affecting domestic cats, particularly in Latin America, where Brazil has documented one of the largest animal disease outbreaks ever recorded [3][5]. The disease is notable for its zoonotic potential, as infected cats can readily transmit the fungus to humans and other animals through bites, scratches, or direct contact with exudate from skin lesions [1]. Globally, feline sporotrichosis has been reported across Latin America, Asia, and other regions, though the epidemiology, causative species, and antifungal susceptibility profiles vary significantly by geography [2][3].

Causative Agents

Feline sporotrichosis is caused by species within the Sporothrix schenckii complex, a group of thermally dimorphic fungi that exist as mycelia in the environment and convert to pathogenic yeast forms at body temperature [1][2]. The primary species implicated include:

• ·Sporothrix brasiliensis: The dominant and most virulent species in Brazil and much of Latin America, responsible for the massive ongoing epidemic [1][3]
• ·Sporothrix schenckii sensu stricto: Found globally including in Latin America and Asia [2]
• ·Sporothrix globosa: Primarily reported in Asia [2]
• ·Sporothrix pallida: Occasionally identified in feline cases [2]

S. brasiliensis is particularly notable for its enhanced virulence and capacity for epidemic spread through cat-to-cat and cat-to-human transmission routes, distinguishing it from other species in the complex [1][3].

Pathological Mechanism

Infection typically begins with traumatic inoculation of fungal conidia or yeast cells into the skin through cat bites, scratches, or contact with contaminated soil or plant material [1][5]. Once inoculated, the organism converts to its yeast phase at 37°C and triggers a granulomatous inflammatory response within the dermis and subcutaneous tissues [1]. The host immune response involves recruitment of neutrophils, macrophages, and lymphocytes, but Sporothrix species possess several virulence factors—including melanin production, thermotolerance, and resistance to phagocytic killing—that allow the organism to survive and replicate intracellularly [1][3].

From the initial cutaneous site, the fungus may spread via lymphatic channels (lymphocutaneous form) or hematogenously to distant organs (disseminated form), including the lungs, eyes, bones, joints, and occasionally the central nervous system [1][5]. Cats are uniquely susceptible to high fungal burdens within lesions compared to other species, which is thought to explain both their severity of disease and their extraordinary efficiency as reservoirs and transmitters of the organism [1][5].

Epidemiology and Transmission

The Brazilian epidemic, centered in Rio de Janeiro, has been ongoing since the late 1990s and by 2012 had already accounted for more than 4,000 feline cases at a single institution [5]. Latin America as a whole represents one of the global epicenters of this disease [3]. In Asia, Malaysia has emerged as a notable focus, where a distinct clonal strain of S. schenckii sensu stricto (clinical clade D) with low susceptibility to major antifungal classes has been identified [2]. Transmission primarily occurs through direct contact with infected cats—via bites, scratches, or aerosol/contact with exudate—making free-roaming intact male cats with fight wounds particularly high-risk animals [1][5].

Clinical Diagnosis

A presumptive diagnosis is based on characteristic clinical signs—multiple ulcerative or nodular cutaneous lesions affecting the face, nasal planum, and extremities in a cat from an endemic region—combined with a history of potential exposure to infected cats or contaminated environments [1][5]. However, clinical presentation alone is insufficient for definitive diagnosis, as lesions can resemble other dermatological conditions including bacterial pyoderma, neoplasia, or other fungal infections.

Cytology

Fine needle aspiration or impression smears of exudate from lesions may reveal round, oval, or cigar-shaped yeast cells (2–6 µm), often intracellularly within macrophages or neutrophils [1][5]. Cats typically harbor a very high fungal load within lesions, making cytology a particularly sensitive and rapid diagnostic tool in this species compared to humans or dogs [5]. Wright-Giemsa or periodic acid-Schiff (PAS) staining facilitates visualization.

Fungal Culture

Culture remains the gold standard for definitive diagnosis and species identification [1]. Samples from exudate, biopsy tissue, or aspirates are inoculated onto Sabouraud dextrose agar and brain-heart infusion agar, typically at both 25°C and 37°C. Sporothrix species demonstrate characteristic thermal dimorphism: white to cream-colored mold colonies at 25°C and cream to tan yeast colonies at 37°C. Identification to species level requires molecular methods such as PCR and sequencing of the calmodulin gene [1][2].

Histopathology

Skin biopsy with histopathological examination reveals pyogranulomatous to granulomatous inflammation in the dermis and subcutis [1][5]. Yeast cells may be visualized with Grocott-Gomori methenamine silver (GMS) or PAS stains. Asteroid body formation (Splendore-Hoeppli phenomenon) may be observed but is not consistently present [5].

Molecular Diagnostics

PCR-based methods targeting species-specific loci allow rapid and accurate species identification and are increasingly used to supplement or replace phenotypic identification, particularly in differentiating S. brasiliensis from S. schenckii and other complex members [1][2].

Antifungal Susceptibility Testing

Given the emergence of strains with reduced susceptibility, particularly in Malaysia and among some Brazilian S. brasiliensis isolates, minimum inhibitory concentration (MIC) testing for itraconazole, terbinafine, and amphotericin B is recommended when available, especially in refractory cases [2][4].

Laboratory Findings

While no pathognomonic hematological or biochemical changes exist, common non-specific abnormalities may include:

• ·Leukocytosis (↑ WBC) with a neutrophilia, reflecting active infection or secondary bacterial involvement
• ·Hyperglobulinemia (↑ GLOB) due to chronic antigenic stimulation and inflammatory response
• ·Hypoalbuminemia (↓ ALB) in cats with chronic disease, poor nutritional status, or protein-losing states
• ·Elevated ALT if hepatic involvement occurs in disseminated disease or as a consequence of prolonged antifungal therapy (particularly itraconazole hepatotoxicity)
• ·Azotemia (↑ BUN, ↑ CREA) in cats with concurrent renal disease or those receiving nephrotoxic therapies such as amphotericin B [1]
• ·Anemia (↓ HCT) of chronic disease may be present in advanced or longstanding infection
• ·Thrombocytopenia (↓ PLT) has been reported in severely ill cats

General Principles

Treatment of feline sporotrichosis requires prolonged antifungal therapy, typically for a minimum of 3–4 months and often extending beyond clinical cure to minimize relapse risk [1]. Treatment selection is guided by disease severity, organ involvement, species identification, antifungal susceptibility results, and drug availability [1][4].

First-Line Antifungal Agents

Itraconazole is considered the primary treatment of choice for feline sporotrichosis in most guidelines [1]. The recommended dose is 5–10 mg/kg orally once daily or divided twice daily, administered with food to enhance absorption. It is a triazole antifungal that inhibits ergosterol biosynthesis and demonstrates good activity against Sporothrix species. Treatment duration is typically a minimum of 2–4 weeks beyond complete clinical resolution [1].

Terbinafine is an allylamine antifungal that inhibits squalene epoxidase and represents an important alternative, particularly in cases where itraconazole is not tolerated or available [1][4]. The dose in cats is 20–30 mg/kg orally once daily. Combination therapy with itraconazole and terbinafine has been used in refractory cases, exploiting synergistic mechanisms of action [1][4].

Emerging Therapies

Miltefosine (Milteforan®), a veterinary alkylphospholipid product originally developed for leishmaniasis, has shown promising in vitro and in vivo activity against S. brasiliensis and S. schenckii sensu stricto, including against strains with reduced susceptibility to conventional antifungals [4]. Its mechanism involves disruption of fungal membrane phospholipid metabolism. Milteforan represents a potentially important addition to the therapeutic armamentarium for refractory or drug-resistant feline sporotrichosis [4].

Second-Line and Salvage Therapy

Amphotericin B (lipid or deoxycholate formulations) may be used in severe, disseminated, or treatment-refractory cases, though nephrotoxicity is a significant concern requiring careful monitoring of renal function (BUN, CREA) [1]. It is typically reserved for life-threatening disease where oral agents have failed.

Potassium iodide, historically used as a treatment for sporotrichosis, is generally not recommended in cats due to species-specific iodine toxicity and poor tolerability [1][5].

Supportive Care

• ·Wound management, including gentle cleaning and debridement of ulcerative lesions
• ·Nutritional support and appetite stimulation in anorectic cats
• ·Treatment of secondary bacterial infections with appropriate antibiotics
• ·Regular hepatic monitoring (ALT) during itraconazole therapy, as hepatotoxicity is a recognized complication
• ·Renal function monitoring if amphotericin B is employed
• ·Pain management as indicated

Zoonotic Precautions During Treatment

Given the high fungal burden in feline lesions and the significant zoonotic risk, handlers must use gloves, protective clothing, and strict hygiene protocols throughout the treatment period [1][3].

Overall Prognosis

The prognosis for feline sporotrichosis is variable and is primarily determined by the extent of disease at presentation, the immune status of the individual cat, the causative Sporothrix species, and the owner's ability to comply with prolonged treatment protocols [1][5]. Cats with localized cutaneous disease generally respond well to appropriate antifungal therapy, while those with disseminated infection, significant comorbidities, or FIV/FeLV coinfection carry a more guarded to poor prognosis [1][5].

Mortality and Outcome Data

Feline sporotrichosis carries a meaningful mortality rate, though treatment-related outcomes vary substantially based on disease form and compliance. A significant proportion of cats in Brazilian studies did not complete treatment due to owner abandonment, drug intolerance, or progressive disease, contributing to high rates of treatment failure and death in field conditions [1][5]. Importantly, a substantial number of cats in the Brazilian epidemic required euthanasia due to advanced disease, welfare concerns, or failure to respond to available therapies—particularly during the early epidemic period when treatment protocols were less established [5]. The literature highlights that prolonged treatment (often exceeding 4–6 months) is necessary and that relapse following premature discontinuation is common [1].

S. brasiliensis-infected cats tend to have a more severe clinical course compared to cats infected with other species, reflecting the higher intrinsic virulence of this organism [1][3]. In Asia, the presence of multidrug-tolerant S. schenckii sensu stricto strains further complicates prognosis in affected populations [2].

Cats coinfected with FIV or FeLV, or those with significant immunosuppression from other causes, face substantially worse outcomes due to impaired host defenses [1][5].

Specific Limitation Note

The available literature does not provide a single universal case-fatality rate expressed as a precise percentage across all forms of feline sporotrichosis. Outcome data are primarily derived from large Brazilian case series and institutional reports; controlled survival statistics with defined denominators across geographic regions remain incompletely characterized in the peer-reviewed literature cited here [1][3][5].

Population-Level Measures

Given the scale of the epidemic in Brazil and the cat's central role as both a victim and reservoir host, control of feline sporotrichosis requires integrated public health and veterinary strategies [1][3]. Key population-level interventions include:

• ·Stray cat population management: Reducing the density of free-roaming, unsterilized cats through trap-neuter-return (TNR) programs and responsible pet ownership campaigns limits cat-to-cat transmission [1][3]
• ·Surveillance and reporting: Active epidemiological surveillance of feline cases to detect outbreaks early and guide public health responses [3]
• ·Public education: Educating the public about zoonotic risks associated with stray cat contact, particularly in endemic regions [3]

Individual Cat Management

• ·Castration: Neutering male cats significantly reduces roaming and fighting behavior, which are the primary routes of cat-to-cat transmission through bite wounds [1][5]
• ·Indoor confinement: Keeping cats indoors eliminates exposure to infected stray cats and contaminated soil or plant material [1]
• ·Wound care: Prompt cleaning and veterinary assessment of any bite or scratch wounds on cats living in or traveling to endemic areas
• ·Avoid contact with infected animals: Cats with suspected or confirmed sporotrichosis should be isolated from other household pets and handled with appropriate personal protective equipment [1]

Vaccination

No commercially available vaccine exists for feline sporotrichosis. Research into immunological approaches is ongoing, but no prophylactic biologic has been validated for clinical use as of the current literature [1].

Zoonotic Prevention for Owners and Veterinary Staff

• ·Wear gloves and long sleeves when handling cats with skin lesions, particularly in endemic regions [1][3]
• ·Educate veterinary personnel about the high zoonotic risk associated with handling infected cats, as numerous cases of human sporotrichosis have been directly traced to infected domestic cats [1][3]
• ·Any human bite or scratch from a cat with suspected sporotrichosis should prompt immediate medical evaluation